Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


A chemically modified thrombolytic agent for reduced intracerebral bleeding risk

  • In: Poster presentation
  • At: Seoul (South Korea) (2017)
  • Type: Poster
  • Poster code: POS-FDP-019
  • By: KWON, Young (Nova Southeastern University, Pharmaceutical Sciences, College of Pharmacy, Fort Lauderdale, United States)
  • Co-author(s): Young M Kwon: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
    Wael Mahdi: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
    Gerardo Ramos: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
  • Abstract:

    Background

    Tissue plasminogen activator (tPA) is the only FDA-approved drug for the treatment of ischemic stroke.  However, tPA is known to stimulate the production of matrix degrading enzymes, which may compromise the integrity of the blood-brain barrier (BBB), leading to intracerebral haemorrhage.  Therefore, a chemically modified thrombolytic..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses